FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159947891> ?p ?o ?g. }

• W2159947891 endingPage "3561" @default.
• W2159947891 startingPage "3555" @default.
• W2159947891 abstract "Peptide receptor radionuclide therapy (PRRT) using somatostatin analogues labeled with beta-particle-emitting isotopes such as 90Y or 177Lu has been a promising treatment strategy for metastasized neuroendocrine tumors. Although remission can be accomplished in a high percentage of neuroendocrine tumors, some tumors do not respond to this treatment. alpha-Emitting isotopes-such as the 10-day half-life alpha-emitting generator nuclide Actinum-225 (225Ac)-are characterized by extremely high cytotoxic activity on the cellular level, and may be superior in the treatment of neuroendocrine tumors not responding to PRRT using beta-emitting isotopes.Radiolabeling of 225Ac 1,4,7,10-tetra-azacylododecane N,N',N'',N'''-J-tetraacetic acid-Tyr3-octreotide (DOTATOC) was done at pH 5 (60 minutes at 70 degrees C) without further purification. Biodistribution in nude mice bearing AR42J rat pancreas neuroendocrine tumor xenografts were measured for up to 24 hours. Toxicity was tested by weight changes, retention variables (blood urea nitrogen and creatine), and histopathology in mice 7 months after treatment with 10 to 130 kBq (n = 4-5). Therapeutic efficacy was assessed by tumor weighing in animals treated 4 days after xenotransplantation and compared with 177Lu-DOTATOC as a reference.Activities up to 20 kBq had no significant toxic effects in mice. In contrast, activities higher than 30 kBq induced tubular necrosis. Biodistribution studies revealed that 225Ac-DOTATOC effectively accumulated in neuroendocrine xenograft tumors. 225Ac-DOTATOC activities were shown to be nontoxic (12-20 kBq), reduced the growth of neuroendocrine tumors, and showed improved efficacy compared with 177Lu-DOTATOC.225Ac might be suitable to improve PRRT in neuroendocrine tumors." @default.
• W2159947891 created "2016-06-24" @default.
• W2159947891 creator A5005390795 @default.
• W2159947891 creator A5009102592 @default.
• W2159947891 creator A5024581793 @default.
• W2159947891 creator A5029333060 @default.
• W2159947891 creator A5051589571 @default.
• W2159947891 creator A5057916984 @default.
• W2159947891 creator A5058718806 @default.
• W2159947891 date "2008-06-01" @default.
• W2159947891 modified "2023-10-05" @default.
• W2159947891 title "Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors" @default.
• W2159947891 cites W1935825021 @default.
• W2159947891 cites W1978689317 @default.
• W2159947891 cites W1990148629 @default.
• W2159947891 cites W2005741240 @default.
• W2159947891 cites W2006402973 @default.
• W2159947891 cites W2011732158 @default.
• W2159947891 cites W2027511464 @default.
• W2159947891 cites W2031465902 @default.
• W2159947891 cites W2034149747 @default.
• W2159947891 cites W2041607504 @default.
• W2159947891 cites W2080585386 @default.
• W2159947891 cites W2098590365 @default.
• W2159947891 cites W2102980902 @default.
• W2159947891 cites W2124325993 @default.
• W2159947891 cites W2135368140 @default.
• W2159947891 cites W2171140185 @default.
• W2159947891 cites W2444395074 @default.
• W2159947891 doi "https://doi.org/10.1158/1078-0432.ccr-07-4647" @default.
• W2159947891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18519789" @default.
• W2159947891 hasPublicationYear "2008" @default.
• W2159947891 type Work @default.
• W2159947891 sameAs 2159947891 @default.
• W2159947891 citedByCount "121" @default.
• W2159947891 countsByYear W21599478912012 @default.
• W2159947891 countsByYear W21599478912013 @default.
• W2159947891 countsByYear W21599478912014 @default.
• W2159947891 countsByYear W21599478912015 @default.
• W2159947891 countsByYear W21599478912016 @default.
• W2159947891 countsByYear W21599478912017 @default.
• W2159947891 countsByYear W21599478912018 @default.
• W2159947891 countsByYear W21599478912019 @default.
• W2159947891 countsByYear W21599478912020 @default.
• W2159947891 countsByYear W21599478912021 @default.
• W2159947891 countsByYear W21599478912022 @default.
• W2159947891 countsByYear W21599478912023 @default.
• W2159947891 crossrefType "journal-article" @default.
• W2159947891 hasAuthorship W2159947891A5005390795 @default.
• W2159947891 hasAuthorship W2159947891A5009102592 @default.
• W2159947891 hasAuthorship W2159947891A5024581793 @default.
• W2159947891 hasAuthorship W2159947891A5029333060 @default.
• W2159947891 hasAuthorship W2159947891A5051589571 @default.
• W2159947891 hasAuthorship W2159947891A5057916984 @default.
• W2159947891 hasAuthorship W2159947891A5058718806 @default.
• W2159947891 hasBestOaLocation W21599478911 @default.
• W2159947891 hasConcept C126322002 @default.
• W2159947891 hasConcept C134018914 @default.
• W2159947891 hasConcept C159654299 @default.
• W2159947891 hasConcept C185592680 @default.
• W2159947891 hasConcept C202751555 @default.
• W2159947891 hasConcept C203014093 @default.
• W2159947891 hasConcept C2776146153 @default.
• W2159947891 hasConcept C2776297358 @default.
• W2159947891 hasConcept C2777807558 @default.
• W2159947891 hasConcept C2779066768 @default.
• W2159947891 hasConcept C2781025020 @default.
• W2159947891 hasConcept C29730261 @default.
• W2159947891 hasConcept C2989005 @default.
• W2159947891 hasConcept C2993559085 @default.
• W2159947891 hasConcept C502942594 @default.
• W2159947891 hasConcept C542903549 @default.
• W2159947891 hasConcept C55493867 @default.
• W2159947891 hasConcept C71924100 @default.
• W2159947891 hasConcept C80115893 @default.
• W2159947891 hasConceptScore W2159947891C126322002 @default.
• W2159947891 hasConceptScore W2159947891C134018914 @default.
• W2159947891 hasConceptScore W2159947891C159654299 @default.
• W2159947891 hasConceptScore W2159947891C185592680 @default.
• W2159947891 hasConceptScore W2159947891C202751555 @default.
• W2159947891 hasConceptScore W2159947891C203014093 @default.
• W2159947891 hasConceptScore W2159947891C2776146153 @default.
• W2159947891 hasConceptScore W2159947891C2776297358 @default.
• W2159947891 hasConceptScore W2159947891C2777807558 @default.
• W2159947891 hasConceptScore W2159947891C2779066768 @default.
• W2159947891 hasConceptScore W2159947891C2781025020 @default.
• W2159947891 hasConceptScore W2159947891C29730261 @default.
• W2159947891 hasConceptScore W2159947891C2989005 @default.
• W2159947891 hasConceptScore W2159947891C2993559085 @default.
• W2159947891 hasConceptScore W2159947891C502942594 @default.
• W2159947891 hasConceptScore W2159947891C542903549 @default.
• W2159947891 hasConceptScore W2159947891C55493867 @default.
• W2159947891 hasConceptScore W2159947891C71924100 @default.
• W2159947891 hasConceptScore W2159947891C80115893 @default.
• W2159947891 hasIssue "11" @default.
• W2159947891 hasLocation W21599478911 @default.
• W2159947891 hasLocation W21599478912 @default.
• W2159947891 hasOpenAccess W2159947891 @default.

• next